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A B S T R A C T
Background
Staphylococcus aureus causes pulmonary infection in young children with cystic fibrosis. Prophylactic antibiotics are prescribed hoping
to prevent such infection and lung damage. Antibiotics have adverse effects and long-term use might lead to infection with Pseudomonas
aeruginosa.
Objectives
To assess continuous oral antibiotic prophylaxis to prevent the acquisition of Staphylococcus aureus versus no prophylaxis in people with
cystic fibrosis, we tested these hypotheses. Prophylaxis:
1. improves clinical status, lung function and survival;
2. causes adverse effects (e.g. diarrhoea, skin rash, candidiasis);
3. leads to fewer isolates of common pathogens from respiratory secretions;
4. leads to the emergence of antibiotic resistance and colonisation of the respiratory tract with Pseudomonas aeruginosa.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from com-
prehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Companies
manufacturing anti-staphylococcal antibiotics were contacted.
Most recent search of Register: 04 September 2014.
Selection criteria
Randomised trials of continuous oral prophylactic antibiotics (given for at least one year) compared to intermittent antibiotics given
’as required’, in people with cystic fibrosis of any disease severity.
Data collection and analysis
The authors assessed studies for eligibility and methodological quality and extracted data.
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Main results
We included four studies, totaling 401 randomised participants aged zero to seven years on enrolment. The two older studies generally
had a higher risk of bias across all domains, but in particular due to a lack of blinding and incomplete outcome data, than the two
more recent studies. We only regarded the most recent study as being generally free of bias, although even here we were not certain of
the effect of the per protocol analysis on the study results.
Fewer children receiving anti-staphylococcal antibiotic prophylaxis had one or more isolates of Staphylococcus aureus. There was no
significant difference between groups in infant or conventional lung function. We found no significant effect on nutrition, hospital
admissions, additional courses of antibiotics or adverse effects. There was no significant difference in the number of isolates of
Pseudomonas aeruginosa between groups, though there was a trend towards a lower cumulative isolation rate of Pseudomonas aeruginosa
in the prophylaxis group at two and three years and towards a higher rate from four to six years. As the studies reviewed lasted six years
or less, conclusions cannot be drawn about the long-term effects of prophylaxis.
Authors’ conclusions
Anti-staphylococcal antibiotic prophylaxis leads to fewer children having isolates of Staphylococcus aureus, when commenced early in
infancy and continued up to six years of age. The clinical importance of this finding is uncertain. Further researchmay establish whether
the trend towards more children with CF with Pseudomonas aeruginosa, after four to six years of prophylaxis, is a chance finding and
whether choice of antibiotic or duration of treatment might influence this.
P L A I N L A N G U A G E S U M M A R Y
Giving antibiotics regularly to people with cystic fibrosis to prevent infection with a germ called Staphylococcus aureus
Review question
We reviewed the evidence about the benefits and adverse effects of giving regular antibiotics to people with cystic fibrosis to prevent
infection with a germ called Staphylococcus aureus.
Background
Cystic fibrosis blocks the airways with mucus and causes frequent airway infections. These can lead to death from breathing failure.
People with cystic fibrosis are sometimes given regular antibiotics to prevent infections from a germ called Staphylococcus aureus.
However, antibiotics can also have adverse effects.
Search date
The evidence is current to: 04 September 2014.
Study characteristics
The review includes four studies with 401 children; there were no adult studies. Volunteers were put into groups at random and
received either an oral antibiotic continuously as a prevention for at least one year or no antibiotic treatment to prevent infection with
Staphylococcus aureus. All volunteers could be given additional antibiotics if their doctor thought they needed them based on symptoms
and germs grown in their respiratory secretions. Studies lasted for a maximum of six years.
Key results
The review found some evidence that giving regular antibiotics to young children (continued up to six years of age) leads to less infection
with Staphylococcus aureus. For other outcomes in the review, there was no difference between giving regular antibiotics or not. Since
none of the studies lasted longer than six years, we can’t draw any conclusions about long-term use. Also, since all studies were in
children, we can not comment on the use of these drugs in adults. Future research should look at patterns of antibiotic resistance and
patient survival.
Quality of the evidence
All the studies were of variable quality. We judged that the two older studies had a higher risk of bias overall compared to the two newer
studies. In particular this was because those taking part in the studies (or their parents or caregivers) would be able to guess which
treatment they were receiving, and also one study did not state if anyone had dropped out and if so what the reasons were. Only the
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newest study seemed to be free of bias, although even here we were not certain if the study results were affected by the way the data
were analysed.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetic disorder characterised by viscid
secretions, primarily affecting the respiratory tract and the gut.
Poor clearance of respiratory secretions and an increased suscep-
tibility to respiratory infection lead to chronic inflammation and
ultimately to bronchiectasis. Most deaths fromCF are due to end-
stage respiratory failure (Kerem 1992).
Bacterial infection due to Staphylococcus aureus (S. aureus) may be
found in CF infants as early as three months of age (Armstrong
1995). Infection in infants with CF is accompanied by evidence of
inflammation and is implicated in the development of lung dam-
age in CF. Many older people with CF acquire chronic infection
with strains of Pseudomonas aeruginosa (P. aeruginosa) and acqui-
sition of this organism is associated with an increase in symptoms
and a decline in lung function (Kerem 1990).
Description of the intervention
Most CF centres treat people with CF with antibiotics when they
are symptomatic, guided by the results of recent specimens of
respiratory secretions. Many will also collect sputum and ’cough
swab’ specimens routinely and prescribe antibiotics if a potential
pathogen is found, even if the person is asymptomatic. People with
CF with advanced lung disease may spend prolonged periods in
hospital receiving courses of intravenous antibiotics.
It is the practice, in some CF centres, to give continuous antibiotic
prophylaxis to people withCF fromdiagnosis. An antibiotic which
is active against S. aureus (such as flucloxacillin) is usually chosen.
How the intervention might work
The aim of prophylactic antibiotic use in this population is to
reduce infection and inflammation in the developing lung and to
slow the onset of bronchiectasis. However, prophylactic antibiotics
may be inconvenient to administer and may be associated with
adverse effects such as diarrhoea or oral candidiasis.
Why it is important to do this review
Of greater concern is the possibility that the use of continuous
antibiotic prophylaxis may lead to colonisation of the respiratory
tract with strains of S. aureus which are resistant to many antibi-
otics (multiple resistant S. aureus or methicillin-resistant S. au-
reus (MRSA)). Furthermore, it has been suggested that the use
of antibiotic prophylaxis might predispose to the acquisition of
chronic infection with P. aeruginosa (Nolan 1982). Finally, the cost
of treatment is appreciable - for an infant one year’s treatment with
flucloxacillin costs more than £200 (US$325) (BNF 2004).
O B J E C T I V E S
To assess the effect of continuous oral antibiotic prophylaxis com-
pared to no prophylaxis to prevent the acquisition of Staphylococ-
cus aureus on the outcome in people with CF. The following hy-
potheses were tested to investigate whether antibiotic prophylaxis:
1. improves clinical status;
2. improves lung function;
3. improves survival;
4. causes adverse effects (diarrhoea, skin rash, candidiasis);
5. leads to fewer isolates of common pathogens from
respiratory secretions;
6. leads the emergence of antibiotic resistance and to the
colonisation of the respiratory tract with organisms such as P.
aeruginosa.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). Cross-over studies were not
considered because we felt this study designwould not allow evalu-
ation of the effects of prophylaxis on long-term outcome measures
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such as lung function, nutrition and the acquisition of resistant
organisms.
Types of participants
People with CF, of any age, diagnosed on the basis of clinical
criteria and sweat testing or genotype analysis.
Types of interventions
Any oral prophylactic antibiotic, used continuously for a period of
at least one year, compared with controls who do not receive pro-
phylactic antibiotics to prevent the acquisition of Staphylococcus
aureus. Both groups could receive intermittent courses of antibi-
otics ’as required’, on the basis of symptoms and organisms found
in respiratory secretions.
Types of outcome measures
Primary outcomes
1. Lung function - forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC)
2. Number of people with one or more isolates of S. aureus
(sensitive strains)
NB: in only one study were the children old enough to perform
the lung function tests. We also included a study measuring infant
lung function.
Secondary outcomes
1. Growth as measured by weight for age and height for age
standard deviation scores*
2. Survival on a yearly basis commencing at one year
3. Number of people admitted to hospital and days spent as
an inpatient
4. Number of people receiving additional antibiotics and
number of days received
5. Number of people with one or more isolates of
Haemophilus influenzae (H. influenzae)
6. Number of people with one or more isolates of P. aeruginosa
7. Acquisition of multiply resistant S. aureus
8. Frequency of adverse effects including: diarrhoea; skin rash;
and oral, nappy or vulval candidiasis
9. Quality of life (if well validated measures are used)
* standard deviation score = observed weight or height - mean/
standard deviation
Search methods for identification of studies
Electronic searches
We identified relevant trials from the Group’s Cystic Fibrosis Tri-
als Register using the terms: antibiotics AND (staphylococcus au-
reus OR mixed infections) AND (preventative treatment OR un-
known) AND (oral OR not stated).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of Embase to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s CF Trials Register:
04 September 2014.
Searching other resources
We have checked the reference lists of the trials on the Cochrane
CF and Genetic Disorders Group relevant to this review to find
any studies not previously identified.
We have contacted the authors of published trials to obtain any un-
published observations or long-term follow-up data.We alsowrote
to the manufacturers of antibiotics commonly used as prophylaxis
to establish if unpublished data are held on file. Tenmanufacturers
were approached: Smith Kline Beecham; Ashbourne Pharmaceu-
ticals; Approved Prescription Services; Galen; Trinity Pharmaceu-
ticals; Yamanouchi Pharma; Bristol Myers Squibb Pharmaceuti-
cals; Glaxo Wellcome; Eli Lilley; and Kent Pharmaceuticals. Five
of these replied, but no new data were uncovered.
Data collection and analysis
Selection of studies
Two authors independently selected studies for inclusion in the
review. The authors resolved disagreements as to which studies
should be included by negotiation.
Data extraction and management
Each author recorded the following: concealment of treatment al-
location; generation of allocation sequence; blinding; and whether
intention-to-treat analysis had been used or was possible from the
4Prophylactic anti-staphylococcal antibiotics for cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
available data. Each author extracted data independently. The au-
thors collected data for the outcome events listed above.
Where possible, the authors reported all outcome measures at
yearly intervals or calculated annualised rates.
Assessment of risk of bias in included studies
In order to assess the risk of bias for each study, two authors inde-
pendently assessed their methodological quality according to the
method described by Schulz (Schulz 1995).
In the current version of the review, the authors assessed the risk of
bias to each included study relative to six domains (sequence gen-
eration, allocation concealment, blinding, incomplete outcome
data, selective reporting and other potential sources of bias) as rec-
ommended by the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). If the generation of allocation
sequence or concealment of that sequence was deemed to be ade-
quate, then the authors judged the study to have a low risk of bias.
If these were deemed to be inadequate, then the authors judged
the study to have a potential risk of bias. If these were unclear, then
the risk of bias for the study was also unclear. For blinding, the
risk of bias was judged to increase as the number of people blinded
to the intervention decreased. The authors also deemed there to
be a risk of bias if there were any withdrawals or drop outs from
the study which were not accounted for and explained, or if there
were an unequal number of drop outs from a particular interven-
tion group. The authors planned to examine the protocol for each
included trial where possible to establish whether results from any
outcomes measured were selectively reported. Where protocols
were not available, the authors compared the ’Methods’ sections of
the published papers to the ’Results’ sections and also used clinical
experience to judge whether they would expect outcomes to be
measured as ’standard’. If they identified any outcomes that had
been clearly measured but not reported, they judged there to be a
high risk of bias; if all outcomes measured were clearly reported,
they judged there to be a low risk of bias; if it was not clear if
outcomes may have been measured and not reported, they judged
there to be an unclear risk of bias. Finally, the authors assessed the
studies for any other potential sources of bias, again judging there
to be a high risk of bias if any sources were identified, a low risk
of bias if it was clear that there were no other sources of bias and
an unclear risk of bias if they were not able to judge this without
any doubts.
Measures of treatment effect
The authors calculated a pooled estimate of treatment effect across
all studies: the odds ratio for dichotomous variables and mean dif-
ference for continuous variables. For longitudinal data, the authors
undertook analysis at six months and thereafter at yearly intervals
from diagnosis.
Unit of analysis issues
The authors did not consider cross-over studies because they felt
this study design would not allow evaluation of the effects of pro-
phylaxis on long-term outcome measures such as lung function,
nutrition and the acquisition of resistant organisms.
Dealing with missing data
Where insufficient data were available from published work, the
authors requested additional data from the trial investigators.
Assessment of heterogeneity
The authors tested for heterogeneity between study results using
the Chi2 test.
Assessment of reporting biases
In future updates of this review, if the authors are able to include
sufficient studies (at least 10), they plan to assess publication bias
by constructing a funnel plot. If the funnel plot is not symmetrical,
publication bias may be present. However, there are other reasons
for funnel plot asymmetry (i.e. heterogeneity), so the authors will
interpret any results with caution. To minimise publication bias,
the authors plan to search trial registries for any unpublished trials
and contact experts in the field.
Data synthesis
The authors analysed the data in the review using a fixed-effect
model. If in future, the authors identify a moderate to high degree
of heterogeneity, they will analyse the data using a random-effects
model.
Subgroup analysis and investigation of heterogeneity
The authors did not plan or undertake any subgroup analyses.
R E S U L T S
Description of studies
Results of the search
Of a total of 18 studies identified by the searches, four studies were
included and 14 studies were excluded .
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Included studies
Four studiesmet the inclusion criteria (Chatfield 1991; Schlesinger
1984; Stutman 2002;Weaver 1994). These studies enrolled a total
of 401 children and provided data from a total of 305 children
(144 boys) who completed treatment per protocol (randomised
to receive either prophylactic antibiotics or no prophylaxis). The
most recently published study is by Stutman and colleagues, who
have supplied data to us directly (Stutman 2002).
A second study (Chatfield 1991) has been the subject of three ab-
stracts (Owen 1991;West 1990;Williams 1988), where only sum-
mary statistics have been presented, and one full paper by Chat-
field, whichmade reference to themethodology, but which did not
present results by antibiotic groups (Chatfield 1991). Individual
patient data have been obtained from the authors and this study
was included in the previous version of this review. Of the remain-
ing studies, one has been published in abstract form (Schlesinger
1984) and the other has been the subject of two publications by
Beardsmore and Weaver (Beardsmore 1994; Weaver 1994).
In the Chatfield study, a neonatal screening programme operated
on alternate weeks and so infants were identified both clinically
and by screening. Randomisation, either to continuous prophy-
lactic flucloxacillin or ’as required’ antibiotic treatment, took place
at diagnosis. Many clinicians declined to randomise infants pre-
senting with meconium ileus, and these infants were therefore ex-
cluded from the analysis (27 infants). In total, 122 infants were
randomised. There were two withdrawals: one child (on prophy-
lactic antibiotics) died at 17 weeks; another child (intermittent
antibiotics) was lost to follow up. No other data were available
on the infants withdrawn. Of the 120 participants who received
treatment per protocol, 54 were randomised to prophylaxis and
66 to ’as required’ treatment.
Schlesinger used a cycle of antibiotics (cotrimoxazole, cefadroxil
and dicloxacillin), with changes being made every three months,
versus the same drugs being used intermittently (Schlesinger
1984). The observation period was one year. Children aged one
to seven years with mild pulmonary disease were studied. Twenty-
eight children were randomised (14 to prophylaxis and 14 to con-
trol). No withdrawals were reported.
In the study by Weaver a single prophylactic antibiotic was used
continuously for two years (flucloxacillin 125 mg twice daily)
(Weaver 1994). In total, 42 infants were randomised and four were
withdrawn (no data available). Of the 38 who received treatment
per protocol, 18 received prophylaxis and 20 ’as required’ treat-
ment.
Stutman and colleagues studied 209 children, from 27 CF centres
in North America, enrolled before two years of age (Stutman
2002). They were diagnosed clinically and randomised to receive
prophylaxis with cephalexin or to receive placebo. The withdrawal
rate was high (90 children withdrawn; 119 completed the study,
of which 68 were in the prophylaxis group and 51 in the placebo
group). When children were withdrawn, this was most commonly
at the parents’ request, due to “the rigors of the study”. Follow up
was for six years.
In each of these studies additional antibiotics could be prescribed
to children in both arms of the study. In the Stutman study, chil-
dren who received an additional antibiotic stopped their prophy-
laxis temporarily and, if additional treatment was required for
more than six weeks, the participant was withdrawn (Stutman
2002). The use of additional antibiotics in all four studies is a
potential confounding factor.
Excluded studies
A total of 14 studies were excluded from the review. Cross-over
studies were not considered (see ’Types of studies’). This resulted
in the exclusion of one study (Loening-Baucke 1979). A study
comparing two prophylactic antibiotics and which did not include
a placebo group was also excluded (Harrison 1985). For similar
reasons, we excluded two studies looking at a group of partic-
ipants receiving oral prophylaxis where an additional antibiotic
was given by aerosol (Nolan 1982) or parenterally (Shapera 1981).
One study was a pharmacokinetic study of linezolid (Keel 2011)
and another study was of a new formulation of tobramycin (Keller
2010). Finally, non-randomised studies were excluded (Ballestero
1992; Brown 1980; Denning 1977; Feigelson 1993; Jensen 1990;
Kerrebijn 1984; Szaff 1982; Wright 1970).
Risk of bias in included studies
In order to establish a risk of bias, the methodological quality of
each study was assessed using the criteria described by Schulz as
adequate, inadequate or unclear (see table ’Characteristics of in-
cluded studies’) relating to a low, high or unclear risk of bias (Schulz
1995). Briefly, these criteria evaluate concealment of treatment al-
location schedule, generation of allocation sequence, blinding and
whether analysis is by intention-to-treat.
Allocation
Two studies described the method of generating the allocation
sequence and was judged to have a low risk of bias (Stutman 2002;
Weaver 1994). The Stutman study randomised participants in
blocks of six, stratified by initial respiratory culture status (Stutman
2002). TheWeaver study employed block randomisation (Weaver
1994). Two studies were described as ’randomised’ but do not
discuss the generation of allocation sequence in their publications;
hence these were judged to have an unclear risk of bias (Chatfield
1991; Schlesinger 1984).
The two studies which described the method of randomisa-
tion, also discussed allocation concealment and the methods were
judged to be adequate leading to a low risk of bias (Stutman 2002;
Weaver 1994). In the Stutman study, all investigators apart from
the study pharmacist were blind to treatment allocation. The phar-
macist was responsible for increasing the dose of the prophylactic
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antibiotic as the children grew (Stutman 2002). In the Weaver
study allocation was given by telephone from the co-ordinating
centre and concealed from the local investigator until the partici-
pant was enrolled (Weaver 1994). The remaining two studies did
not discuss concealment of allocation and were judged to have an
unclear risk of bias (Chatfield 1991; Schlesinger 1984).
Blinding
Only one of the included studies was double-blinded and placebo
controlled (Stutman 2002). The authors judged this study to have
a low risk of bias.
The other three studies were not blinded and did not use a placebo
(Chatfield 1991; Schlesinger 1984; Weaver 1994). These studies
were judged to have a potential risk of bias.
Incomplete outcome data
One study did not report any participants withdrawn from the
study (Schlesinger 1984). Two studies performed analysis on those
participants who completed the study and did not provide any
data on participants withdrawn from the studies (Chatfield 1991;
Weaver 1994). Chatfield reported data on varying numbers of par-
ticipants at one, two and three year time points (Chatfield 1991).
Weaver stated that analysis was per protocol (Weaver 1994). In
the Stutman study, analysis was per protocol (outcome variables
measured yearly up to six years of age) (Stutman 2002). The au-
thors also analysed data on those completing at least one year of
the study, although this does not constitute a formal intention-to-
treat analysis (Stutman 2002). The use of per protocol analysis in
the Stutman study will tend to favour the intervention.
Selective reporting
The authors judged two studies to have a low risk of bias; one study
reported outcome variables at one and two years following study
entry (Weaver 1994); another study measured and reported those
stated outcomes yearly up to six years of age (Stutman 2002).
The authors judged two studies to have an unclear risk of bias.
One study reported outcome variables at only one year after en-
rolment; furthermore, the protocol was not available and since
this study has only been published as a abstract, the authors were
unable to compare any detailed methods with results (Schlesinger
1984). The final study reported outcomes up to three years of age;
however as stated above, only summary statistics have been pre-
sented in the three abstracts published for this study and the only
full paper describes the methodology but does not present results
by antibiotic groups (Chatfield 1991).
Other potential sources of bias
For one study there is a high risk of bias as the original data were
published only in abstract form and the authors cannot be traced
(Schlesinger 1984).
In each of these studies additional antibiotics could be prescribed
to children in both arms of the study and the use of additional
antibiotics is a potential confounding factor. However, the authors
still judge there to be is a low risk of bias for this domain for the
other three studies as they have not identified any other potential
sources of bias (Chatfield 1991; Stutman 2002; Weaver 1994).
One study stated that the investigators performed a sample-size
calculation when designing the trial (Stutman 2002).
Effects of interventions
Data from three studies could be combined (Chatfield 1991;
Stutman 2002; Weaver 1994). In each case data on participants
completing the study per protocol were used. The Stutman study
is the only one giving data beyond three years and hence graph-
ical data for years four, five and six refer to the Stutman study
alone (Stutman 2002). In these three studies, additional antibi-
otics could be given to children receiving prophylaxis, when they
were unwell, and so prophylaxis is evaluated as an adjunct to ’as
required’ treatment.
Primary outcomes
1. Lung function
Stutman used conventional tests of lung function, measured at
the end of follow up (six years) (Stutman 2002). They found no
significant difference between prophylaxis and placebo for FEV1,
mean difference (MD) 0.00 (95% confidence interval (CI) -0.08
to 0.08) or FVC, MD 0.10 (95% CI 0.01 to 0.19).
Infant lung function was measured by Beardsmore in the Weaver
study, which looked at infants enrolled in the newborn period
(Beardsmore 1994). The authors aimed to measure lung function
shortly after diagnosis (achieved in 19 infants receivingprophylaxis
and 18 on ’as required’ treatment) and again at one year (achieved
in 18 infants receiving prophylaxis and 17 on ’as required’ treat-
ment). Specialised tests of lung function (not in routine clinical
practice) were used, namely: thoracic gas volume (TGV); airway
conductance (Gaw); maximum flow at functional residual capac-
ity (Vmax FRC). The study authors reported no significant differ-
ence in infant lung function between the two regimens at either
age. The results were expressed as scores (the number of standard
errors by which the participant’s value differed from a predicted
value). For the mean values of scores, please refer to the additional
table (Table 1).
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2. Number of people with one or more isolates of S. aureus
(sensitive strains)
Reporting of the presence of organisms in the respiratory secre-
tions is difficult to standardise, since prevalence is dependent on
the frequency with which samples are taken. The eligible studies
involved young children and so nose and throat swabs were used,
rather than sputum samples. Armstrong showed that oropharyn-
geal specimens predict lower respiratory infection poorly (positive
predictive value 41%) (Armstrong 1996).
The Weaver study reported the number of children in whom an
organism was found and the number of months when there were
positive isolates (Weaver 1994). However, the methods section
does not specify how often routine samples were taken. For the
sake of clarity and comparability, the data presented in ’Data and
analyses’ show the number of children with at least one isolate of
S. aureus. Pooled data from the Chatfield, Stutman and Weaver
studies were used and are presented by years in the study from
one to six years (Chatfield 1991; Stutman 2002; Weaver 1994).
These data show significantly fewer children with one or more
isolates of S. aureus (at any time from the start of the study) in
the group receiving prophylaxis for every year of follow up (see
’Analysis 1.2’).
Schlesinger reported only the results of throat swabs at the be-
ginning and end of the one-year prophylaxis period (Schlesinger
1984). The results are given for S. aureus only:
Start of study: prophylaxis = 2 out of 14; ’as required’ treatment
= 7 out of 14
End of study: prophylaxis = 0 out of 14; ’as required’ treatment =
5 out of 14
Given the lower prevalence of S. aureus at the start of this study in
participants who were subsequently randomised to prophylaxis,
the finding that S. aureuswas isolated fromnone of the participants
receiving prophylaxis at the end of the study must be interpreted
with caution. The results do not give cumulative isolation rates
for the one-year study period and so are not included in ’Data and
analyses’.
Secondary outcomes
1. Growth
Four studies measured children’s growth (Chatfield 1991;
Schlesinger 1984; Stutman 2002; Weaver 1994). Schlesinger re-
ported the weight for age standard deviation score (Z score) after
12 months and found a statistically significant difference in favour
of the children receiving prophylaxis; the statistical test used and
the level of significance were not stated (Schlesinger 1984). The
results from the Schlesinger study could not be presented graphi-
cally as the standard deviations were not given. Stutman and col-
leagues gave mean weight and height in each group, at the end
of six years follow up (no significant difference) (Stutman 2002).
However, standard deviation scores were not given.
Weaver recorded weight for age and length for age standard devi-
ation scores at six months, one year and two years (Weaver 1994).
Chatfield recorded the same standard deviation scores at one, two
and three years (Chatfield 1991). The results for the one- and two-
year assessment have therefore been combined. The combined
data from the two studies did not find a statistically significant
difference in either the weight for age or the length for age stan-
dard deviation scores, in favour of either regimen, at either the
one- or two-year time points (see ’Analysis 1.3; Analysis 1.4’). The
standard deviation scores at six months and three years, for the
individual studies, are also presented in ’Data and analyses’. Again,
there was no significant difference in favour of either regimen.
Length is difficult to measure accurately in this age group.
2. Survival
This could not be included in the graphs as an outcome. No deaths
were reported in three studies (Schlesinger 1984; Stutman 2002;
Weaver 1994). One death was reported in the prophylaxis group
in the other study, but no details were published (Chatfield 1991).
3. Number of people admitted to hospital and days spent as
an inpatient
Frequency of hospital admissions was reported in three studies
(Chatfield 1991; Stutman 2002; Weaver 1994). There was no
significant difference between the two regimens in the number
of participants having at least one hospital admission, odds ratio
(OR) 0.96 (95% CI 0.50 to 1.86).
Themeannumber of days spent in hospital per child per year of the
study was calculated for three studies (Chatfield 1991; Stutman
2002; Weaver 1994). There was no significant difference between
the two regimens, MD 0.88 (95% CI -1.35 to 3.10).
4. Number of people receiving additional antibiotics and
number of days received
Weaver described number of additional ’courses’ of antibiotics
given but did not define the length of a course (Weaver 1994).
These data have therefore not been presented in graphical form.
Additional antibiotic treatment was not reported in three studies
(Chatfield 1991; Schlesinger 1984; Stutman 2002). There was
no significant difference between groups for either the number of
children receiving additional antibiotics, OR 0.18 (95% CI 0.01
to 3.60), or for the mean number of days received per child, MD
-37.10 (95% CI -78.73 to 4.53).
5. Number of people with one or more isolatesH.
inﬂuenzae
Only one study reported isolates of H. influenzae (Weaver 1994).
This study found no significant difference between the two reg-
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imens in the number of children from whom H. influenzae was
isolated, OR 0.64 (95% CI 0.18 to 2.31).
6. Number of people with one or more isolates of P.
aeruginosa
This was not reported by Schlesinger (Schlesinger 1984). When
the results of the Chatfield, Stutman and Weaver studies were
combined, there were no significant differences between groups
for this outcome (Chatfield 1991; Stutman 2002; Weaver 1994).
However, the results suggest that this outcome may depend on the
duration of treatment. As shown in the graph ’Analysis 1.10’, after
two and three years of treatment there was a trend towards fewer
isolates of P. aeruginosa in the treatment group, but at years four,
five and six the trend was towards fewer isolates of P. aeruginosa in
the control group. However, only one study followed children up
for four years or more (Stutman 2002).
Weaver reported isolates of P. aeruginosa in both upper respiratory
and stool specimens (Weaver 1994). There was no significant dif-
ference in the isolation rate from stools in children on the two
regimens.
7. Acquisition of multiply resistant S. aureus
None of the studies reported isolation of resistant organisms such
as MRSA or Burkholderia cepacia.
8. Adverse effects of prophylactic antibiotics
These data were presented in one study (Stutman 2002). There
was no significant difference between the groups in the occurrence
of generalised rash, MD 0.40 (95% CI -0.07 to 0.87); nappy rash,
MD 0.90 (95% CI -1.06 to 2.86); or increased stool frequency,
MD 0.20 (95% CI -2.18 to 2.58).
9. Quality of life
Quality of life parent or child was not reported in any of the
studies.
Additional outcomes which have arisen from the
review
1. Clinical and radiological scoring
Although this was not an a priori hypothesis of this review,
data from the Chatfield study are available for Shwachman and
Chrispin-Norman scores at three years (Chatfield 1991). The
Shwachman score is a clinical scorewhich includes symptoms, clin-
ical examination findings, nutrition and radiology (Shwachman
1958). The Chrispin-Norman score is an objective chest radio-
graph score (Chrispin 1974). There was no significant difference
in either the Shwachman score,MD -0.23 (95%CI -2.97 to 2.51),
or the Chrispin-Norman score, MD -0.27 (95%CI -1.05 to 0.51)
in the 119 children in whom data were available at three years.
D I S C U S S I O N
Cumulative data on 305 participants from the four included stud-
ies indicate that fewer children in the group receiving continuous
anti-staphylococcal prophylaxis had one or more isolates of S. au-
reus (Chatfield 1991; Schlesinger 1984; Stutman 2002; Weaver
1994). However, the pooled data do not show complete eradica-
tion of S. aureus with the use of prophylaxis. We found no signif-
icant difference in the isolation rate of other common organisms
(such as H. influenzae and Streptococcus pneumoniae) between the
prophylaxis and ’as required’ groups.
Although there was no significant difference between groups in
the number of children having one or more isolates of P. aerug-
inosa, there was a trend towards fewer affected children in years
two and three of the study and a similar trend to more children
having at least one isolate of P. aeruginosa in years four to six. The
data from the years four to six all come from one study (Stutman
2002), as none of the other studies had more than three years
of follow up. These trends may be a chance finding. However,
if the trend to more children having P. aeruginosa with a longer
duration of prophylaxis is a genuine finding, then this is a cause
for concern. There are two possible explanations: firstly, a period
of prophylaxis of more than three years’ duration predisposes to
pseudomonas infection; or secondly, the use of a broad-spectrum
antibiotic (cephalexin) rather than a narrow spectrum anti-staphy-
lococcal antibiotic (flucloxacillin) predisposes to pseudomonas in-
fection.
These possibilities should be investigated in a properly designed
trial. After three years of prophylaxis, children could be ran-
domised to stop prophylaxis or continue, and further randomised
to receive either broad- or narrow-spectrum antibiotics. Many CF
centres advocate lifelong prophylactic anti-staphylococcal antibi-
otics, which means there will be a much longer treatment period
when adverse outcomes can be observed. In this respect, the risk
of acquiring P. aeruginosa is cumulative over time and any factor
which marginally increases this risk may only become evident dur-
ing longer periods of follow up. The risk will also be affected by
the treatment policy used in a clinic, for treating early infection
with P. aeruginosa and by strategies used to prevent cross infection.
Data are presented for a number of clinical outcome measures:
nutrition; Shwachman score; and Chrispin-Norman chest radio-
graph score. Nutritional data are available from three eligible
studies (Chatfield 1991; Schlesinger 1984; Weaver 1994). One
study suggested an improvement in weight for age standard devi-
ation score in the prophylaxis group after one year of treatment
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(Schlesinger 1984). This study could not be combined with the
other two studies reporting standard deviation scores (Chatfield
1991; Weaver 1994). The pooled data from the studies of Chat-
field and Weaver show no significant difference in weight for
age or height for age standard deviation scores between regimens
(Chatfield 1991;Weaver 1994). TheChatfield study provides data
up to three years, again with no significant difference seen. This
may be because this study looked at young children who are still
showing rapid ’catch up’ growth (Morison 1997), whereas the par-
ticipants studied by Schlesinger may have already achieved this
’catch up’ in weight. Alternatively, this negative result may be be-
cause there is no therapeutic effect. The data from the Chatfield
study showed no significant difference in Shwachman orChrispin-
Norman scores between the two regimens (Chatfield 1991).
The requirement for additional antibiotics and hospital admission
may be thought of as indirect measures of clinical status, although
both thesemeasures will be influenced by local treatment protocols
and clinicians’ preferences. The use of additional antibiotics is
also a potential confounding factor. Admissions to hospital may
also have a negative effect on the quality of life of the child and
their family. The pooled data show no significant difference in
additional antibiotics or hospital admissions between groups.
The reference by Beardsmore for the Weaver study suggests that
antibiotic prophylaxis has no significant effect on infant lung func-
tion over a one-year period (Beardsmore 1994). This result is per-
haps not surprising because a clinically important change in lung
function over such a brief period would be unlikely. The measures
of lung function used were of a specialised nature and are not
available as a routine clinical test in most centres. Stutman found
no significant difference in FEV1 or FVC between the two groups
after six years of follow up (Stutman 2002).
The eligible studies had a maximum follow-up period of six years
and all the participants studied were under seven years of age. It
is therefore important not to extrapolate these results to longer
periods of prophylaxis or to older individuals. Only one death
was reported in one of the eligible studies, and so no conclusions
can be drawn about the likely effects of prophylaxis on survival.
Mortality is likely to be very low in the young children studied
and during such a short follow-up period.
In common with other Cochrane authors (Walters 1999), we have
found it difficult to establish whether the randomisation method
used in many studies allows true concealment of allocation and
therefore prevents bias. It is to be hoped that medical journals
will increasingly follow the recommendations of the CONSORT
statement on reporting the results of randomised controlled tri-
als (Moher 2001). One of the eligible studies included in this re-
view by Schlesinger did not report withdrawals, making it im-
possible to determine whether intention-to-treat or per protocol
analysis had been used (Schlesinger 1984). The two citations of
the Weaver study contained discrepancies in the number of par-
ticipants in prophylaxis and ’as required’ groups (Weaver 1994).
This suggests that data on lung function have been presented on
some (but not all) of the participants who withdrew from the
study. The Chatfield study has a number of methodological weak-
nesses (Chatfield 1991). There was a lack of proper randomisation
of infants with meconium ileus, leading to their exclusion from
our analysis. Neonatal screening was undertaken only on alternate
weeks leading to a heterogeneous population, containing screened
and unscreened infants, being randomised to prophylaxis or in-
termittent treatment. Data were not available on every child in
the study at each time point of follow up. This has led to data
on different numbers of children being reported at different time
points. For an example of this, see the graphs in Statistical Anal-
ysis for weight and length standard deviation score at one, two
and three years. This is a potential source of bias. The Stutman
study was methodologically superior in having a clear description
of concealment of allocation, allocation sequence generation, and
double-blinded placebo-controlled design (Stutman 2002). How-
ever, even in this study, formal intention-to-treat analysis was not
possible due to a lack of outcome data on those children who were
withdrawn.
Overall the number of studies is small, and those studies which
have been undertaken are of poor quality, with small numbers of
participants. The effect on S. aureus is likely to be genuine, as it is
seen in all three studies taken individually and when they are com-
bined in the meta-analysis. It is also consistent at all time points
up to six years. However, the lack of a beneficial effect of prophy-
laxis on any outcome measure other than S. aureus may be gen-
uine or due to insufficient statistical power, bias or the ’lumping’
together of different regimens. The data on P. aeruginosamust be
interpreted with caution, as there was no statistically significant
difference between regimens. Data for this outcome measure for
years four to six came from the Stutman study alone, where at-
trition may have led to bias (Stutman 2002). The Stutman study
was the only study to report on adverse effects and uncommon
adverse effects may be missed in randomised trials because of the
small numbers involved (Stutman 2002).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review includes four studies of anti-staphylococcal antibiotic
prophylaxis in children with CF, with data from 305 participants.
The quality of studies is concerning, with important deficiencies
in each. Significantly fewer children with CF will have one or
more isolates of S. aureus in upper respiratory secretionswhen anti-
staphylococcal antibiotic prophylaxis is prescribed for the first six
years of life. However, the importance of this finding is uncertain,
as this review has not shown that this is associated with an im-
provement in clinical outcome measures. The currently available
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evidence does not allow conclusions to be drawn regarding the
effect of prophylaxis on acquisition of P. aeruginosa. There is no
significant difference in the rate of common adverse effects.
There is insufficient evidence in this review to say whether the use
of anti-staphylococcal antibiotic prophylaxis in older children or
adults is beneficial or harmful. Hence, clinicians should exercise
caution, if prophylactic anti-staphylococcal antibiotics are used in
older individuals or for longer periods.
Implications for research
A number of studies, which were considered for this review, have
been published only in abstract form or as methodological pa-
pers. Nonetheless, it is likely that important questions, such as the
influence of prophylaxis on antibiotic resistance patterns and on
patient survival, will remain unanswered. These issues can only
be addressed by long-term follow-up studies, with careful bacte-
riological and clinical surveillance. It may be that a randomised
intervention with antibiotic prophylaxis in children of three years
and over, coupled with data collection via the evolving UK CF
database (or its equivalent in other countries), might provide a
suitable model for future research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chatfield 1991
Methods Randomised controlled trial.
Participants Infants with CF diagnosed by neonatal screening or clinically (alternate weeks).
Total enrolled = 122 (2 withdrew, n = 120, prophylaxis = 54, ’as required’ = 66).
Mean age at enrolment 18 weeks for prophylaxis & 22 weeks for ’as required’.
Followed up to age three years. Data available at one, two & three years
Interventions Continuous oral flucloxacillin versus intermittent antibiotics ’as required’
Outcomes *Secondary outcome 1. Growth.
Secondary outcome 3. Inpatient days.
Secondary outcome 5. Participants with isolates of common pathogens.
Secondary outcome 6. P. aeruginosa.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described, unclear.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded. No placebo.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat analysis: not possible (infants with
meconium ileus not randomised and therefore excluded
from analysis). One participant lost to follow up and one
infant died
Selective reporting (reporting bias) Unclear risk Study reported outcomes up to three years of age. Only
summary statistics have been presented in abstracts,
and full paper describes the methodology, but does not
present results by antibiotic groups
Other bias Low risk No other potential source of bias identified.
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Schlesinger 1984
Methods Randomised controlled trial.
Participants Children aged 1 to 7 years with mild CF lung disease.
28 participants enrolled, no withdrawals documented (prophylaxis = 14, ’as required’ =
14).
Mean age at enrolment 42 months for prophylaxis & 53 months for ’as required’.
Similar Z-scores for weight & height on enrolment.
Important differences in prevalence of S. aureus in prophylaxis (2/14) & ’as required’
groups (7/14) on enrolment.
Follow up for 1 year. Data collected at enrolment & 1 year.
Interventions Co-trimoxazole, or cefadroxil, or dicloxacillin in 3-monthly cycles for 1 year
Outcomes Secondary outcome 1. Growth.
Secondary outcome 5. Participants with isolates of common pathogens
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described, unclear.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded. No placebo.
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis: not possible, (numbers as-
sessed for eligibility and participants withdrawn not de-
scribed)
Selective reporting (reporting bias) Unclear risk Study reported outcome variables at only one year after
enrolment. Published as abstract only, so not able to
compare Methods and Results sections
Other bias High risk The original data were published only in abstract form
and the authors cannot be traced
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Stutman 2002
Methods Randomised controlled trial.
Participants Children under 2 years.
209 enrolled, 90 withdrew & 119 completed the study (68 prophylaxis, 51 ’as required’)
.
Mean age at enrolment (prophylaxis = 14.1 months, ’as required’ = 12.7 months).
Followed up for between 5 & 7 years. Data collected at yearly intervals from year 1
Interventions Continuous cephalexin versus placebo.
Outcomes Primary outcome 1. Lung function.
Secondary outcome 1. Growth.
Secondary outcome 3. Inpatient days.
Secondary outcome 4. Courses of ’as required’ oral antibiotics.
Secondary outcome 5. Participants with isolates of common pathogens.
Secondary outcome 6. P. aeruginosa.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participant stratified by respiratory culture status. Per-
muted block design (blocks of 6, with 3 participants in
each block randomised to cephalexin or placebo)
Allocation concealment (selection bias) Low risk Treatment allocation known only to the study pharma-
cist. The pharmacist was responsible for increasing the
dose of the prophylactic antibiotic as the children grew
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded & placebo-controlled.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Formal intention-to-treat analysis: not possible. How-
ever, analysis performed of children completing treat-
ment per protocol (n = 119) and those completing at
least 1 year of the trial (n = 165)
Selective reporting (reporting bias) Low risk Measured and reported stated outcome variables yearly
up to six years of age
Other bias Low risk No other potential source of bias identified.
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Weaver 1994
Methods Randomised (block randomisation) controlled trial. Allocation was given by telephone
from the co-ordinating centre and concealed from the local investigator until the partic-
ipant was enrolled
Participants Infants with CF diagnosed by neonatal screening.
42 participants enrolled, 4 withdrew (n = 38 prophylaxis = 18, ’as required’ = 20).
Similar mean ages at enrolment (7 weeks for prophylaxis, 5 weeks for ’as required’).
Followed up to age 2 years. Data collected at 6 months, 1 & 2 years
Interventions Continuous oral flucloxacillin versus intermittent antibiotics ’as required’
Outcomes Primary outcome 1. Lung function.
Secondary outcome 1. Growth.
Secondary outcome 2. Inpatient days.
Secondary outcome 4. Courses of ’as required’ oral antibiotics.
Secondary outcome 5. Participants with isolates of common pathogens
Secondary outcome 6. P. aeruginosa.
Secondary outcome 7. MRSA.
Notes Additional information from authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised in the published
paper.
Authors confirmed treatment was allocated
on the basis of block randomisation and
allocation was given by telephone from the
co-ordinating centre
Allocation concealment (selection bias) Low risk Allocationof treatmentwas concealed from
the local investigator until the participant
was enrolled
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded. No placebo.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat analysis: not possible.
Selective reporting (reporting bias) Low risk Study reported outcome variables at one
and two years following study entry
Other bias Low risk Noother potential source of bias identified.
*Numbering of outcomes relates to order of outcomes in text of review.
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CF: cystic fibrosis
MRSA: methicillin-resistant Staphylococcus aureus
P. aeruginosa: Pseudomonas aeruginosa
S. aureus: Staphylococcus aureus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ballestero 1992 Non-randomised.
Brown 1980 Non-randomised.
Denning 1977 Non-randomised.
Feigelson 1993 Non-randomised.
Harrison 1985 Both participant groups received prophylaxis. Comparison was not made with a group receiving intermittent
antibiotics ’as required’
Jensen 1990 Non-randomised.
Keel 2011 Pharmacokinetic study of linezolid.
Keller 2010 Study of new formulation of tobramycin for use in treating Pseudomonas aeruginosa.
Kerrebijn 1984 Non-randomised.
Loening-Baucke 1979 Cross-over study design.
Nolan 1982 All participants on oral prophylaxis (cloxacillin). Nebulised cephaloridine given to alternate participants in
a quasi-randomised design
Shapera 1981 Parenteral and oral clindamycin versus oral clindamycin alone
Szaff 1982 Non-randomised.
Wright 1970 Non-randomised.
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D A T A A N D A N A L Y S E S
Comparison 1. Continuous, oral, anti-staphylococcal antibiotic prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lung function 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 FEV1 at 6 years 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 FVC at 6 years 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Number of children from whom
S. aureus isolated at least once
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 1 year 2 248 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.15, 0.48]
2.2 2 years 3 315 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.13, 0.35]
2.3 3 years 2 260 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.13, 0.38]
2.4 4 years 1 127 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.04, 0.25]
2.5 5 years 1 98 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.03, 0.26]
2.6 6 years 1 43 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.03, 0.46]
3 Z score weight (6 months to 3
years)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 6 months 1 32 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.54, 1.14]
3.2 1 year 2 133 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.50, 0.26]
3.3 2 years 2 140 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.33, 0.45]
3.4 3 years 1 112 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.58, 0.30]
4 Z score length (6 months to 3
years)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 6 months 1 23 Mean Difference (IV, Fixed, 95% CI) 0.52 [-0.36, 1.40]
4.2 1 year 2 127 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.36, 0.48]
4.3 2 years 2 134 Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.65, 0.19]
4.4 3 years 1 112 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.50, 0.36]
5 Number of children requiring
admission (annualised rates)
3 243 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.50, 1.86]
6 Days in hospital (annualised
rates)
3 242 Mean Difference (IV, Fixed, 95% CI) 0.88 [-1.35, 3.10]
7 Number of children receiving
additional antibiotics
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Days of additional antibiotics 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Number of children from whom
H. influenzae isolated at least
once
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 2 years 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Number of children from
whom P. aeruginosa isolated at
least once
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 1 year 2 247 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.77, 2.60]
10.2 2 years 3 315 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.45, 1.23]
10.3 3 years 2 261 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.51, 1.51]
10.4 4 years 1 127 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.62, 2.64]
10.5 5 years 1 98 Odds Ratio (M-H, Fixed, 95% CI) 1.97 [0.85, 4.58]
10.6 6 years 1 43 Odds Ratio (M-H, Fixed, 95% CI) 3.67 [0.77, 17.35]
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11 Adverse effects 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Generalised rash 1 119 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.07, 0.87]
11.2 Nappy rash 1 119 Mean Difference (IV, Fixed, 95% CI) 0.90 [-1.06, 2.86]
11.3 Increased stool frequency 1 119 Mean Difference (IV, Fixed, 95% CI) 0.20 [-2.18, 2.58]
12 Shwachman score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 3 years 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Chrispin-Norman Score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 3 years 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Results of infant lung function testing (Beardsmore 1994)
Measurement Prophylaxis (start) As required (start) Prophylaxis (1 year) As required (1 year)
TGV (thoracic gas vol-
ume)
0.05 0.98 -0.22 0.09
Gaw (airway conduc-
tance)
1.16 0.00 -1.79 -1.13
Vmax FRC (maximum
flow at functional resid-
ual capacity)
-0.69 -0.75 -0.61 -0.85
(All lung function values
expressed as standard er-
ror scores)
WH A T ’ S N E W
Last assessed as up-to-date: 20 November 2014.
Date Event Description
20 November 2014 New search has been performed An updated search of the Cystic Fibrosis & Genetic
Disorders Review Group’s Cystic Fibsrosis Trials Reg-
ister did not identify any new references which were
potentially eligible for inclusion in this review
The Plain Language Summary has been updated in
line with new guidance
20 November 2014 New citation required but conclusions have not
changed
No new information has been added to this review,
therefore our conclusions remain the same
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H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 1, 2000
Date Event Description
30 October 2012 New citation required but conclusions have not
changed
No new data were included at this update and so the
conclusions of the review remain the same
30 October 2012 New search has been performed A new search of the Group’s Cystic Fibrosis Trials Reg-
ister identified two new references potentially eligible
for inclusion in this review both of which were ex-
cluded (Keel 2011; Keller 2010).
13 September 2010 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified no studies which were potentially relevant
for inclusion in the review
12 August 2009 Amended Contact details updated.
9 September 2008 Amended Converted to new review format.
2 September 2008 New search has been performed A new search of the Group’s trials register was run but
no new references were identified
23 May 2007 New search has been performed A new search of the Group’s trials register was run but
no new references were identified
24 May 2006 New search has been performed A new search of the Group’s trials register was run but
no new references were identified
23 February 2005 Amended To more accurately reflect the content and scope of
the review, the title was changed from ’Prophylactic
antibiotics for cystic fibrosis’
23 February 2005 New search has been performed A new search was run but no new references were iden-
tified.
29 April 2004 New search has been performed A new search was run but no new references were iden-
tified.
20 May 2003 New citation required and conclusions have changed Substantive amendment.
Since the previous version of this review, the results
of a large North American trial of cephalexin versus
placebo have been published (Stutman 2002). The au-
thors have made further data available, allowing us to
evaluate the effect of prophylaxis on conventional lung
function tests, number of people receiving additional
antibiotics, days of additional treatment and adverse
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(Continued)
effects. This further data also allows pooling of data
on the following outcomemeasures: number of people
admitted to hospital, duration of admission, isolates S.
aureus, and isolates of P. aeruginosa. Our earlier find-
ings of a beneficial effect on the number of children
with one or more isolates of S. aureus, are confirmed.
There is no significant difference in the number of
isolates of P. aeruginosa between groups, though there
is a trend towards fewer children with one or more
isolates of P. aeruginosa infection, with prophylaxis, in
years two and three and a similar trend towards more
children with P. aeruginosa from years four to six.
21 March 2001 New search has been performed We have received individual patient data on 109 chil-
dren at two-year follow up who were enrolled in the
Wales and West Midlands neonatal screening study
(reported by Chatfield 1991). The published report
did not include analysis by allocation to the prophy-
laxis or intermittent treatment group. We have now
gone back to the original data and undertaken this
analysis. This has allowed pooling of data on the fol-
lowing outcome measures: nutrition, isolates of com-
mon pathogens, isolates of P. aeruginosa, number of
children admitted to hospital, and duration of admis-
sion. Our earlier findings of a beneficial effect of pro-
phylaxis on the frequency of isolation of S. aureus from
upper respiratory secretions are confirmed. Pooled data
demonstrate no effect on nutrition. There is a non-sig-
nificant trend towards a lower prevalence of P. aerugi-
nosa infection with prophylaxis.
C O N T R I B U T I O N S O F A U T H O R S
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The authors included a further outcome after the protocol was published: Clinical and radiological scoring. Although this was not an
a priori hypothesis of this review, data from the Chatfield study are available for Shwachman and Chrispin-Norman scores at three
years (Chatfield 1991). The Shwachman score is a clinical score which includes symptoms, clinical examination findings, nutrition and
radiology (Shwachman 1958). The Chrispin-Norman score is an objective chest radiograph score (Chrispin 1974).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antibiotic Prophylaxis; Cystic Fibrosis [∗microbiology]; Infant, Newborn; Pseudomonas aeruginosa [isolation & purification]; Ran-
domized Controlled Trials as Topic; Respiratory Tract Infections [∗prevention & control]; Staphylococcal Infections [∗prevention &
control]; Staphylococcus aureus [∗isolation & purification]
MeSH check words
Child; Child, Preschool; Humans; Infant
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